Etodesnitazene
[CAS# 14030-76-3]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyrimidine compound >> Amine
• Name: Etodesnitazene
• Synonyms: 2-[2-[(4-ethoxyphenyl)methyl]benzimidazol-1-yl]-N,N-diethylethanamine
• Molecular Formula: C₂₂H₂₉N₃O
• Molecular Weight: 351.49
• CAS Registry Number: 14030-76-3
• SMILES: CCN(CC)CCN1C2=CC=CC=C2N=C1CC3=CC=C(C=C3)OCC

Properties

• Melting point: 65-66 ºC

Discovory and Applicatios

Etodesnitazene, a potent opioid analgesic, was first synthesized and described in scientific literature in 2018. It belongs to the benzimidazole opioid class and is structurally related to other powerful opioids like etonitazene and desnitroetonitazene. The discovery of etodesnitazene was part of ongoing research aimed at developing novel opioid compounds with potent analgesic effects.

Etodesnitazene exhibits high affinity and efficacy at the mu opioid receptor, making it a potent analgesic. It has been studied for its potential use in managing severe pain, including cancer pain and postoperative pain. However, like other opioids, its use is associated with the risk of tolerance, dependence, and overdose, necessitating cautious prescribing and close monitoring.

Etodesnitazene serves as a valuable tool in scientific research aimed at understanding opioid pharmacology and receptor signaling pathways. Its high potency allows researchers to study opioid receptor function, receptor-ligand interactions, and the mechanisms underlying opioid-induced analgesia and side effects.

Etodesnitazene has gained attention in forensic toxicology due to its emergence in illicit drug markets. Its presence in forensic samples, such as seized drugs and postmortem specimens, requires accurate detection and quantification methods to aid in drug enforcement efforts and provide information on the prevalence and distribution of novel synthetic opioids.

Despite its potent analgesic effects, the use of etodesnitazene as a pharmaceutical drug is limited due to its high potency, abuse potential, and adverse effects. However, its structural scaffold and pharmacological profile serve as a basis for the design and development of novel opioid analgesics with improved safety and efficacy profiles.

Like other potent opioids, etodesnitazene poses significant public health risks, including overdose-related morbidity and mortality. Its emergence in illicit drug markets highlights the ongoing challenge of synthetic opioid misuse and the need for comprehensive strategies to address opioid-related harms.

References

2023. Identification of the Putative Binding Site of a Benzimidazole Opioid (Etazene) and Its Metabolites at �-Opioid Receptor: A Human Liver Microsomal Assay and Systematic Computational Study. Molecules (Basel, Switzerland). Krishna Chaturvedi, Isuru Hewamanna, Pankaj Pandey, Washim Khan, Yan-Hong Wang, Amar Chittiboyina, Robert Doerksen, Murrell Godfrey.
DOI: 10.3390/molecules28041601

2022. Identification of etazene (etodesnitazene) metabolites in human urine by LC-HRMS. Drug Testing and Analysis. Nick Verougstraete, Annick Verhaeghe, Jan Germonpr�, Herve Lebbinck, Alain G. Verstraete.
DOI: 10.1002/dta.3377

2020. Etazene (N,N-diethyl-2-{[(4-ethoxyphenyl)methyl]-1H-benzimidazol-1-yl}-ethan-1-amine (dihydrochloride)): a novel benzimidazole opioid NPS identified in seized material: crystal structure and spectroscopic characterization. Forensic Toxicology. Marta Siczek, Marcin Zawadzki, Milosz Siczek, Agnieszka Chlopas-Konowalek, Pawel Szpot.
DOI: 10.1007/s11419-020-00552-9